Machine Learning

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

IO Biotech’s cancer vaccine posts impressive 5-year survival data, but a narrow miss in its pivotal trial creates an uncertain path in a competitive market.

Beyond a routine board re-election, Heidmar Maritime is doubling down on an AI-driven strategy to navigate the volatile tanker market. Here's what it means.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Beyond fiber and 5G, the most vital infrastructure is human talent. A new scholarship is empowering the next generation of innovators to build it.

A popular countertop choice is fueling a deadly, incurable lung disease among workers, sparking a public health crisis and a race for safer alternatives.

A new collaboration aims to transform market noise into actionable foresight, moving beyond simple bets to offer a unified view of the global economy.

An ISG report names Rackspace a leader in AI-driven cloud services, revealing how it helps midmarket firms master cost, complexity, and security.

A new law requires work verification for millions on Medicaid. One tech firm has a solution, but can its AI bridge the gap or widen the access divide?

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

Odysight.ai's new sensors offer a live video feed from inside hot, oil-filled machinery, a breakthrough poised to transform industrial predictive maintenance.

Rail Vision just secured a key European patent for its AI collision avoidance tech. Is this IP fortress enough to challenge giants and define the future of rail?

With a dual listing on Brazil's B3 exchange, DeFi Technologies isn't just expanding—it's building a strategic blueprint for institutional crypto adoption.

A fintech firm's new hire seems distant, but it signals a crucial shift in how capital flows into life-saving research and healthcare innovation.

Natera's legal retreat solidifies a major victory for NeoGenomics, clearing the runway for its RaDaR ST launch and shaking the diagnostic patent landscape.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

Vanda Pharmaceuticals submits its novel GPP therapy, imsidolimab, for FDA review, offering new hope for patients and bolstering its rare disease portfolio.

The crypto giant reports massive growth, but a pivot to AI, operational fires, and rising debt reveal a risky strategy to reshape global computing power.

As New Jersey's cannabis market booms, Grown Rogue's one-year success reveals a potent strategy for blending craft quality with low-cost execution.